AM-37 and ST-36 Are Small Molecule Bombesin Receptor Antagonists.

While peptide antagonists for the gastrin-releasing peptide receptor (BB2R), neuromedin B receptor (BB1R), and bombesin (BB) receptor subtype-3 (BRS-3) exist, there is a need to develop non-peptide small molecule inhibitors for all three BBR. The BB agonist (BA)1 binds with high affinity to the BB1R, BB2R, and BRS-3. In this communication, small molecule BBR antagonists were evaluated using human lung cancer cells. AM-37 and ST-36 inhibited binding to human BB1R, BB2R, and BRS-3 with similar affinity (Ki = 1.4-10.8 µM). AM-13 and AM-14 were approximately an order of magnitude less potent than AM-37 and ST-36. The ability of BA1 to elevate cytosolic Ca2+ in human lung cancer cells transfected with BB1R, BB2R, and BRS-3 was antagonized by AM-37 and ST-36. BA1 increased tyrosine phosphorylation of the EGFR and ERK in lung cancer cells, which was blocked by AM-37 and ST-36. AM-37 and ST-36 reduced the growth of lung cancer cells that have BBR. The results indicate that AM-37 and ST-36 function as small molecule BB receptor antagonists.

Introduction

The <span class="Gene">bombesin (BB) family of peptides is biologically active in the ce<span class="Gene">ntral nervous system (CNS) and periphery. BB, a 14 amino acid peptide isolated from frog skin, has 9 of the 10 same C-terminal amino acids as does human gastrin-releasing peptide (GRP), a 27 amino acid peptide (1). GRP binds with high affinity to the BB2R, which regulates pruritus, lung development, and gastrin secretion. Neuromedin B (NMB) is a 10 amino acid peptide with 70% sequence homology to the C-terminal of BB. NMB binds with high affinity to the BB1R and causes satiety, hypothermia, and thyrotropin (TSH) secretion from the pituitary (2). BB receptor subtype-3 (BRS-3) is an orphan receptor with homology to the BB1R and BB2R, and binds the universal agonist, BB agonist (BA)1, with high affinity as does the BB1R and BB2R (3). Because BRS-3 knockout mice have impaired energy balance, glucose homeostasis, and increased body weight, BRS-3 agonists may function as satiety agents (4). In the CNS, GRP and NMB may act in a paracrine manner being released from brain neurons in the hypothalamus and dentate gyrus, respectively, activating BB2R and BB1R in adjacent cells (5).

In <span class="Disease">numerous cancers, including <span class="Disease">lung cancer, GRP and NMB function in an autocrine manner to stimulate cellular proliferation. Small cell lung cancer (SCLC), a neuroendocrine tumor, has high levels of GRP (6, 7). GRP is secreted from SCLC and binds to cell surface BB2R resulting in increased cellular proliferation (8). NMB is present in both SCLC and non-small cell lung cancer (NSCLC) cells, and after secretion it binds to cell surface BB1R stimulating proliferation (9). Because many lung cancer cells have BB1R, BB2R, and/or BRS-3 there is a need to develop antagonists that block all three receptors of the BB family.

The <span class="Species">human <span class="Gene">BB1R, BB2R, and BRS-3 contain 390, 384, and 399 amino acids and have approximately 50% sequence homology. The BB1R, BB2R, and BRS-3 are members of the rhodopsin β group G protein-coupled receptors (GPCR) family, and they interact with Gq causing phosphatidylinositol (PI) turnover (10). PI-4,5-bisphosphate (PIP2) is metabolized to diacylglycerol, which activates protein kinase C and inositol-trisphosphate (IP3) which causes elevated cytosolic Ca2+. Neuropeptide receptors regulate the transactivation of the epidermal growth factor (EGF) receptor leading to NSCLC proliferation (11). The proliferation of NSCLC cells caused by BA1 can be inhibited by the tyrosine kinase inhibitor (TKI) gefitinib or BBR antagonists. The actions of BA1 on BB1R, BB2R, and BRS-3 are antagonized selectively by PD168368, PD176252, and Bantag-1, respectively (12).

In the present study, small molecules were synthesized and their ability to antagonize <span class="Gene">BB1R, <span class="Gene">BB2R, and BRS-3 in lung cancer cells evaluated. The results indicate that AM-37 and ST-36 are useful agents to inhibit the growth of NSCLC cells which have BB1R, BB2R, or BRS-3.

Materials and Methods

Cell Culture

<span class="Disease">Non-small cell lung cancer cell line <span class="CellLine">NCI-H1299 (ATCC, Manassas, VA, USA) was stably transfected with BB1R, BB2R, and BRS-3. The transfected cells were grown in RPMI-1640 containing 10% fetal bovine serum (FBS) with 0.3 mg/ml geneticin (Invitrogen, Grand Island, NY, USA). The transfected cells, which contained approximately 100,000 receptors/cell, were weekly split using trypsin/EDTA (13). In addition, lung cancer cell lines NCI-H727, H1299, and H1975 were purchased from ATCC and cultured in RPMI-1640, which contained 10% FBS. The cell types were derived from different human biopsy specimens. These studies were approved by the NIDDK biospecimens and biosafety committees.

Ligand Synthesis

The small molecules were synthesized as described previously (14). Figure 1D shows the structural formula of <span class="Chemical">AM-37, (R)-3-(1H-indol-3-yl)-2-[3-(4-methoxyphenyl)ureido]-N-[[1-(3-pyridinyl)cyclohexyl]methyl]propanamide, and of its S-enantiomer <span class="Chemical">ST-36. Figure 1E shows the structural formula of AM-13, (R)-N-[[1-(4-fluorophenyl)cyclohexyl]methyl]-3-(1H-indol-3-yl)-2-[3-(4-methoxyphenyl)ureido]propanamide, and its S-enantiomer AM-14. The molecular weight of AM-37 and ST-36 is 525.6 Da, whereas the molecular weight of AM-13 and AM-14 is 542.2 Da.

Figure 1

Binding. The ability of varying concentrations of AM-37 (●), ST-36 (■), AM-13 (▲), and AM-14 (▼) to inhibit specific 125I-BA1 binding was investigated using (A) BB1R-, (B) BB2R-, and (C) BRS-3-transfected NCI-H1299 cells. The mean value ± SD of three determinations each repeated in duplicate is shown. (D) The structure of AM-37 and ST-36 is shown. (E) The structure of AM-13 and AM-14 is shown; *indicates the optically active site.

Binding. The ability of varying conce<span class="Gene">ntrations of <span class="Chemical">AM-37 (●), ST-36 (■), AM-13 (▲), and AM-14 (▼) to inhibit specific 125I-BA1 binding was investigated using (A) BB1R-, (B) BB2R-, and (C) BRS-3-transfected NCI-H1299 cells. The mean value ± SD of three determinations each repeated in duplicate is shown. (D) The structure of AM-37 and ST-36 is shown. (E) The structure of AM-13 and AM-14 is shown; *indicates the optically active site.

Receptor Binding

The ability of <span class="Chemical">AM-37, <span class="Chemical">ST-36, AM-13, and AM-14 to inhibit specific 125I-BA1 binding to NSCLC cells transfected stably with BB1R, BB2R, and BRS-3 was investigated. NSCLC cells were placed in 24 well plates. When confluent, the cells were washed three times with PBS. The cells were incubated with binding buffer (PBS containing 0.25% bovine serum albumin and 0.025% bacitracin, Sigma-Aldrich, St. Louis, MO, USA). Various concentrations of AM-37, ST-36, AM-13, or AM-14 were added to the cells for 10 min, followed by 100,000 cpm of 125I-BA1 (0.16 nM) and incubated at 37°C for 30 min when equilibrium of binding was reached. The cells were rinsed three times with binding buffer for 2 min at 4°C. The cells that contained bound peptide dissolved in 0.2 N NaOH and counted in a Wallac 1470 γ-counter. The Ki was calculated as described (15).

Cytosolic Ca2+

The ability of <span class="Chemical">AM-37, <span class="Chemical">ST-36, AM-13, and AM-14 to function as BBR antagonists was investigated. NSCLC cells transfected with BB1R, BB2R, and BRS-3 were harvested and loaded with Fura-2AM (Calbiochem, La Jolla, CA, USA) as described previously (16). The excitation ratio was determined at 340 and 380 nm with an emission wavelength of 510 nm. The lung cancer cellular calcium response was determined after the addition of AM-37, ST-36, AM-13, or AM-14 followed by 10 nM BA1.

Tyrosine Phosphorylation

The <span class="Chemical">tyrosine phosphorylation of the <span class="Gene">EGFR and ERK was investigated by western blot. NSCLC cells transfected with BB1R, BB2R, and BRS-3 were placed in 10 cm dishes. When the cells were confluent, they were placed in SIT medium (RPMI-1640 containing 3 × 10−8 M sodium selenite, 5 µg/ml bovine insulin, and 10 µg/ml apo-transferrin; Sigma-Aldrich, St. Louis, MO, USA) for 3 h. AM-37, ST-36, AM-13, or AM-14 were added for 30 min followed by 100 nM BA1 for 2 min. Cell extracts were made as described previously (16), and 600 µg of protein extract was immunoprecipitated with 4 µg anti-phosphotyrosine antibody (Becton Dickenson, USA). The immunoprecipitates were fractionated using a 4–20% polyacrylamide gel (Novex, San Diego, CA, USA). Proteins were transferred to a nitrocellulose membrane and incubated with 2 µg anti-EGFR or anti-ERK antibody (Cell Signaling Technologies, Danvers, MA, USA). After washing the blot, it was incubated with enhanced chemiluminescence detection reagent (Thermo Scientific) for 5 min and exposed to Biomax XAR film (Carestream, Rochester, NY, USA). The band intensity was determined using a Kodak image station 440 densitometer. Alternatively, 20 µg of protein extract was loaded onto polyacrylamide gels and after transfer to nitrocellulose, the blot was probed with anti-PY1,068-EGFR, anti-EGFR, anti-PY204ERK, or anti-ERK (Cell Signaling Technologies, Danvers, MA, USA).

Proliferation

The proliferation of <span class="Disease">NSCLC cells was investigated using the <span class="Chemical">3-(4,5-demethylthiazol-2-yl)-2,3-diphenyl-2H-tetrazolium bromide (MTT) assay as described previously (16). NCI-H727, H1299, and H1975 cells were placed in SIT medium and varying concentration of AM-37, ST-36, AM-13, or AM-14 added. After 2 days, 0.1% MTT solution (15 µl) was added. After 4 h, DMSO (150 µl) was added and the absorbance at 570 nm was determined.

Statistical Analysis

The results are expressed as the mean ± SD. Statistical significance of differences was performed by a one-way or two-way repeated measures of variance. The binding curves were drawn using PRISM.

Results

The ability of the small molecules to bind to BB1R, BB2R, and BRS-3 was investigated. AM-37 (R-enantiomer) inhibited specific 125I-BA1 binding to BB1R, BB2R, and BRS-3 in a dose-dependent manner with Ki values 3.6, 1.4, and 5.5 µM, respectively (Figure 1). ST-36 (S-enantiomer) inhibited specific 125I-BA1 binding to BB1R, BB2R, and BRS-3 with Ki values of 7.9, 6.9, and 10.8 µM, respectively (Figure 1). In contrast, AM-13 (R-enantiomer) and AM-14 (S-enantiomer) inhibited specific 125I-BA1 binding to BB1R, BB2R, and BRS-3 with Ki > 20 µM. The results indicate that AM-37and ST-36 bind to BB1R, BB2R, and BRS-3 with greater affinity than does AM-13 and AM-14.

The specificity of binding was investigated. Table 1 shows that BA1 bound with high affinity (Ki = 0.002, 0.0005, and 0.004 µM) to BB1R, BB2R, and BRS-3. AM-37, ST-36, AM-13, and AM-14 inhibited specific 125I-BA1 binding (Ki = 1.4, 6.9, 27, and 45 µM) to BB2R. ST-36 inhibited specific 125I-BA1 binding (Ki = 7.9 and 10.8 µM) to BB1R and BRS-3, respectively. AM-13 and AM-14 bind with low affinity to BB1R and BRS-3 (Ki > 100 µM and >100 μM, respectively).

Table 1

Binding to lung cancer cells transfected with human bombesin receptors.

Ligand	Ki, μM
	BB1R	BB2R	BRS-3
BA1	0.002 ± 0.0002	0.0005 ± 0.0001	0.004 ± 0.0003
AM-37	3.6 ± 0.5	1.4 ± 0.2	5.5 ± 0.6
ST-36	7.9 ± 0.9	6.9 ± 0.3	10.8 ± 0.9
AM-13	>100	27 ± 4	>100
AM-14	>100	45 ± 8	>100

The mean value ± SD of four determinations is indicated. The structure of bombesin agonist 1 is (D-Tyr.

BRS-3, bombesin receptor subtype-3.

Binding to <span class="Disease">lung cancer cells transfected with <span class="Species">human bombesin receptors.

The mean value ± SD of four determinations is indicated. The structure of <span class="Gene">bombesin agonist 1 is (D-Tyr.

<span class="Gene">BRS-3, bombesin receptor subtype-3.

The ability of the small molecules to function as BB1R, BB2R, and BRS-3 antagonists was investigated. Addition of 10 nM BA1 to NCI-H1299 cells transfected with BB1R increased the cytosolic Ca2+ from 160 to 178 nM within seconds (Figure 2A). The response was transient and returned to baseline after 1 min. Addition of 30 µM AM-37 to NCI-H1299 cells transfected with BB1R had no effect on the basal cytosolic Ca2+ but blocked the increase in cytosolic Ca2+ caused by BA1 (Figure 2B). Addition of 30 µM AM-14 had no effect of basal cytosolic Ca2+ but partially blocked the increase caused by 10 nM BA1 (Figure 2C). Table 2 shows that AM-37 and AM-14 significantly inhibited the ability of BA1 to increase cytosolic Ca2+ after addition to NCI-H1299 cells transfected with BB1R. Addition of 10 nM BA1 to NCI-H1299 cells transfected with BB2R increased the cytosolic Ca2+ from 160 to 186 nM (Figure 2D). Addition of 30 µM ST-36 to NCI-H1299 cells transfected with BB2R had no effect on the basal cytosolic Ca2+ but blocked the increase in cytosolic Ca2+ caused by BA1 (Figure 2E). Addition of 30 µM AM-14 had no effect of basal cytosolic Ca2+ but partially blocked the increase caused by 10 nM BA1 (Figure 2F). Table 2 shows that ST-36 and AM-14 significantly decreased the ability of 10 nM BA1 to elevate cytosolic Ca2+ in NCI-H1299 cells transfected with BB2R. Addition of 10 nM BA1 to NCI-H1299 cells transfected with BRS-3 increased the cytosolic Ca2+ from 170 to 194 nM (Figure 2G). Addition of 30 µM ST-36 to NCI-H1299 cells transfected with BRS-3 had no effect on the basal cytosolic Ca2+ but blocked the increase in cytosolic Ca2+ caused by BA1 (Figure 2H). Addition of 30 µM AM-13 had no effect of basal cytosolic Ca2+ but partially blocked the increase caused by 10 nM BA1 (Figure 2I). Table 2 shows that ST-36 and AM-13 significantly decreased the ability of 10 nM BA1 to elevate cytosolic Ca2+ in NCI-H1299 cells transfected with BRS-3. The results indicate that AM-37 and ST-36 are antagonists for BB1R, BB2R, and BRS-3. In contrast, AM-13 and AM-14 are weak antagonists for the BBR family.

Figure 2

Cytosolic Ca2+. The ability of (A) 10 nM bombesin agonist 1 (BA)1 and 10 nM neurotensin (NT), (B) 30 µM AM-37 followed by 10 nM BA1 and 10 nM NT, and (C) 30 µM AM-14 followed by 10 nM BA1 and 5 µg/ml ionomycin (ION) to increase cytosolic Ca2+ was determined as a function of time after the addition to NCI-H1299 cells transfected with BB1R. The ability of (D) 10 nM BA1 and 10 nM NT, (E) 30 µM ST-36 followed by 10 nM BA1 and 10 nM NT, and (F) 30 µM AM-14 followed by 10 nM BA1 and 5 µg/ml ION to increase cytosolic Ca2+ was determined as a function of time after the addition to NCI-H1299 cells transfected with BB2R. The ability of (G) 10 nM BA1 and 10 nM NT, (H) 30 µM ST-36 followed by 10 nM BA1 and 10 nM NT, and (I) 30 µM AM-13 followed by 10 nM BA1 and 5 µg/ml ION to increase cytosolic Ca2+ was determined as a function of time after the addition to NCI-H1299 cells transfected with bombesin receptor subtype-3. This experiment is representative of three others.

Table 2

Increases in cytosolic Ca2+ using human lung cancer cells transfected with bombesin receptors.

Addition	Increase in cytosolic Ca2+, nM
	BB1R	BB2R	BRS-3
BA1, 10 nM	18.5 ± 1.1	26.3 ± 1.7	24.4 ± 2.3
BA1 + AM-37, 30 µM	1 ± 0.6a	0a	0a
BA1 + ST-36, 30 µM	0a	0a	0a
BA1 + AM-13, 30 µM	7 ± 0.8a	5 ± 0.6a	2 ± 0.3a
BA1 + AM-14, 30 µM	6 + 0.6a	6 + 0.5a	3 + 0.4a

The initial increase in the cytosolic Ca.

BRS-3, bombesin receptor subtype-3, BA1, bombesin agonist 1.

Cytosolic <span class="Chemical">Ca2+. The ability of (A) 10 nM <span class="Gene">bombesin agonist 1 (BA)1 and 10 nM neurotensin (NT), (B) 30 µM AM-37 followed by 10 nM BA1 and 10 nM NT, and (C) 30 µM AM-14 followed by 10 nM BA1 and 5 µg/ml ionomycin (ION) to increase cytosolic Ca2+ was determined as a function of time after the addition to NCI-H1299 cells transfected with BB1R. The ability of (D) 10 nM BA1 and 10 nM NT, (E) 30 µM ST-36 followed by 10 nM BA1 and 10 nM NT, and (F) 30 µM AM-14 followed by 10 nM BA1 and 5 µg/ml ION to increase cytosolic Ca2+ was determined as a function of time after the addition to NCI-H1299 cells transfected with BB2R. The ability of (G) 10 nM BA1 and 10 nM NT, (H) 30 µM ST-36 followed by 10 nM BA1 and 10 nM NT, and (I) 30 µM AM-13 followed by 10 nM BA1 and 5 µg/ml ION to increase cytosolic Ca2+ was determined as a function of time after the addition to NCI-H1299 cells transfected with bombesin receptor subtype-3. This experiment is representative of three others.

Increases in cytosolic <span class="Chemical">Ca2+ using <span class="Species">human lung cancer cells transfected with bombesin receptors.

<span class="Gene">BRS-3, bombesin receptor subtype-3, <span class="Chemical">BA1, bombesin agonist 1.

The specificity of <span class="Chemical">AM-37, <span class="Chemical">ST-36, AM-13, and AM-14 was investigated. 10 nM neurotensin (NT) or 5 µg/ml ionomycin (ION) strongly increased the cytosolic Ca2+ in NSCLC cells. AM-37 or ST-36 had no effect on the ability of NT to increase cytosolic Ca2+ in NSCLC cells. AM-13 or AM-14 had no effect on the ability of ION to increase Ca2+ in NSCLC cells. Therefore, AM-36 and ST-37 are antagonists for the BBR but not the NTR.

The ability of the small molecules to impair EGFR transactivation was investigated. Previously, we found that the BB1R and BRS-3 regulate EGFR tyrosine phosphorylation (13, 16). Figure 3 shows that addition of 100 nM BA1 to NCI-H1299 cells transfected with BB2R increased significantly the EGFR tyrosine phosphorylation to 326%. If the cells were pretreated with 10 µM AM-37 or ST-36, addition of BA1 had little effect. In contrast, if the cells were treated with 10 µM AM-13, BA1 increased strongly EGFR tyrosine phosphorylation. Similarly, BA1 addition to NCI-H1299 cells transfected with BB2R increased ERK tyrosine phosphorylation to 277%. This increase in ERK tyrosine phosphorylation was decreased significantly in the cells pretreated with AM-37 or ST-36 but not AM-13. Similarly, AM-14 had little effect on EGFR or ERK tyrosine phosphorylation (data not shown). The results indicate that AM-37 and ST-36 antagonize the ability of the BB2R to regulate tyrosine phosphorylation of the EGFR and ERK. Similar transactivation results were obtained for NSCLC cells transfected with BB1R or BRS-3 (data not shown).

Figure 3

Western blot. (Top) The ability of 100 nM bombesin agonist (BA)1 to increase EGFR and ERK tyrosine phosphorylation was investigated using NCI-H1299 cells transfected with BB2R in the presence of 10 µM AM-37, 10 µM ST-36, and 10 µM AM-13. (Bottom) BA1 or BA1 plus AM-13 increased significantly EGFR and ERK tyrosine phosphorylation relative to the control, whereas total ERK and EGFR were unaltered; p < 0.01; ** by ANOVA. The control, BA1 + AM-37, and BA1 + ST-36 were significantly reduced relative to BA1; p < 0.01, aa by ANOVA. The experiment is representative of three others.

Western blot. (Top) The ability of 100 nM <span class="Gene">bombesin agonist (BA)1 to increase <span class="Gene">EGFR and ERK tyrosine phosphorylation was investigated using NCI-H1299 cells transfected with BB2R in the presence of 10 µM AM-37, 10 µM ST-36, and 10 µM AM-13. (Bottom) BA1 or BA1 plus AM-13 increased significantly EGFR and ERK tyrosine phosphorylation relative to the control, whereas total ERK and EGFR were unaltered; p < 0.01; ** by ANOVA. The control, BA1 + AM-37, and BA1 + ST-36 were significantly reduced relative to BA1; p < 0.01, aa by ANOVA. The experiment is representative of three others.

The ability of the small molecules to inhibit <span class="Disease">lung cancer proliferation was investigated. <span class="Chemical">AM-37 inhibited NCI-H1299 proliferation in a dose-dependent manner. Figure 4 shows that AM-37 had little effect at 3 µM but strongly inhibited proliferation at 30 µM. The IC50 for AM-37 was 16 µM. Similarly, ST-36 had an IC50 of 22 µM, whereas AM-14 was less potent (IC50 > 50 µM).

Figure 4

MTT assay. The ability of varying doses of AM-37 (○), ST-36 (●), and AM-14 (■), to inhibit the proliferation of NCI-H1299 cells is shown. The mean value ± SD of eight determinations is indicated. This experiment is representative of two others.

MTT assay. The ability of varying doses of <span class="Chemical">AM-37 (○), <span class="Chemical">ST-36 (●), and AM-14 (■), to inhibit the proliferation of NCI-H1299 cells is shown. The mean value ± SD of eight determinations is indicated. This experiment is representative of two others.

The specificity of the small molecules was investigated. Table 3 shows that AM-37, ST-36, AM-13, and AM-14 (50 µM) inhibited significantly the proliferation of NCI-H727 cells, which have mRNA for BB1R, BB2R, and BRS-3. In contrast, AM-37, ST-36, AM-13, and AM-14 had little effect on NCI-H1975 cells, which lack BB1R, BB2R, and BRS-3. These results indicate that the BBR is essential for AM-37, ST-36, AM-13, or AM-14 to inhibit cancer cellular proliferation.

Table 3

MTT proliferation assay using human lung cancer cell lines.

Addition	% proliferation
	NCI-H727	NCI-H1975
None	100 ± 5	100 ± 6
AM-37, 50 µM	13 ± 1aa	103 ± 5
ST-36, 50 µM	30 ± 3aa	95 ± 5
AM-13, 50 µM	67 ± 4a	89 ± 5
AM-14, 50 µM	64 ± 3a	88 ± 6

The ability of AM-37, ST-36, AM-13, and AM-14 to inhibit non-small cell lung cancer growth was determined using NCI-H727, which express BB.

MTT proliferation assay using <span class="Species">human <span class="Disease">lung cancer cell lines.

The ability of <span class="Chemical">AM-37, <span class="Chemical">ST-36, AM-13, and AM-14 to inhibit non-small cell lung cancer growth was determined using NCI-H727, which express BB.

Discussion

While <span class="Disease">NSCLC <span class="Species">patients are traditionally treated with combination chemotherapy, the 5-year survival rate is only 16% (17). Some NSCLC patients (13%) have L858R EGFR mutations, and these patients respond to TKI such as gefitinib or erlotinib; however, secondary EGFR mutations can occur such as T790M resulting in TKI resistance (18). Numerous GPCR are expressed in lung cancer cell lines and biopsy specimens. BB2R mRNA is expressed in 46–67% of the lung cancer cell lines examined (19). BB1R mRNA is present in 81% of the NSCLC cell lines examined (20). Using autoradiographic techniques, BRS-3 binding sites were detected in 40% of the lung cancer biopsy specimens examined (21). The EGFR is abundant on NSCLC (approximately 100,000 EGFR/cell), whereas BBR are present on most native NSCLC cells (approximately 2,000 BBR/cell) (22).

Addition of GRP to <span class="Disease">NSCLC cells causes transactivation of the <span class="Gene">EGFR (23). The effects of GRP on NSCLC tyrosine phosphorylation of the EGFR are impaired by gefitinib, a TKI, and PD176252, a peptoid BB2R antagonist. Because the ERK and EGFR tyrosine phosphorylation caused by GRP was impaired by marimastat, GM6001 and antibodies to TGFα, matrix metalloproteases may regulate the cellular shedding of TGFα from NSCLC cells. The TGFα may then bind to the EGFR causing its tyrosine phosphorylation. The results indicate that the BB2R regulates EGFR transactivation in NSCLC cells.

The <span class="Gene">BB1R regulates <span class="Gene">EGFR transactivation (16). The increase in EGFR and ERK tyrosine phosphorylation caused by NMB addition to NSCLC cells was impaired by PD168368, a BB1R peptoid antagonist, as well as gefitinib. The increase in EGFR tyrosine phosphorylation caused by NMB was impaired by N-acetyl cysteine (NAC), an antioxidant, or tiron, a superoxide scavenger. NMB increased reactive oxygen species (ROS) in NSCLC cells, and the increase was inhibited by Tiron. It remains to be determined if the ROS impair protein tyrosine phosphatases in NSCLC cells, which remove phosphate from the P-EGFR. Activation of BRS-3 with BA1 increased EGFR and ERK tyrosine phosphorylation (13). The increase in EGFR tyrosine phosphorylation caused by BA1 is impaired by NAC, tiron, and diphenyleneiodonium, an inhibitor of NADPH oxidase enzymes.

<span class="Chemical">ML-18 is a small molecule that prefers <span class="Gene">BRS-3 relative to BB1R or BB2R (24). ML-18, an S-enantiomer, inhibits 125I-BA1 binding to BRS-3, BB2R, and BB1R with IC50 values of 4.8, 16, and >100 μM, respectively, whereas the R-enantiomer EMY-98 is inactive. ML-18 is a BRS-3 antagonist, which inhibits the ability of BA1 to increase cytosolic Ca2+, increase ERK and EGFR tyrosine phosphorylation (24). Also, ML-18 inhibited NSCLC growth and increased the cytotoxicity of gefitinib. His107 is important for BRS-3 to bind antagonists with high affinity (25). Tyr101 of the BB2R is important for binding of non-peptide antagonists (26). Similarly, this Tyr is conserved in the BB1R and BRS-3. It remains to be determined if this Tyr is essential for binding of AM-37 to the BB1R, BB2R, or BRS-3. ST-36, which is an S-enantiomer, inhibited specific 125I-BA1 binding to BB1R, BB2R, and BRS-3 with IC50 values of 7.9, 6.9, and 10.8 µM, respectively. It is surprising that AM-37, which is the R-enantiomer, binds with slightly higher affinity to BBR than does ST-36. Previously, the BB1R was found to prefer PD168,368, which is an S-isomer, relative to the R-isomer (27).

(D-<span class="Gene">Arg1, <span class="Chemical">D-Trp5,7,9, Leu11)substance P (SP) is an inhibitor of signal transduction and growth of SCLC cells (28). (D-Arg1, D-Trp5,7,9, Leu11)SP impaired the ability of BB, vasopressin, or bradykinin to increase cytosolic Ca2+ and ERK activity. (D-Arg1, D-Trp5,7,9, Leu11)SP decreased SCLC growth in vitro, and (D-Arg1, D-Trp5,7,9, Leu11)SP has a unique tertiary structure in with two type IV non-standard turns, which juxtapose the N- and C-terminal adjacent to one another (29). Due to this unique structure (D-Arg1, D-Trp5,7,9, Leu11)SP may be able to interact with multiple GPCR. In contrast, AM-37 and ST-36 are small molecules that have a different structure from that of (D-Arg1, D-Trp5,7,9, Leu11)SP.

<span class="Chemical">AM-37 and <span class="Chemical">ST-36 inhibited the proliferation of NSCLC cells such as NCI-H1299 and H727, which have BB1R, BB2R, or BRS-3. In contrast, AM-37 and ST-36 have little effect on NSCLC cell line NCI-H1975, which lacks BB1R, BB2R, and BRS-3. It remains to be determined if AM-37 or ST-36 are synergistic with gefitinib at inhibiting the growth of NSCLC. A goal is to identify GPCR antagonists, which potentiate the action of TKI in NSCLC patients.

Conclusion

<span class="Chemical">AM-37 and <span class="Chemical">ST-36 are small molecules, which bind to the BB1R, BB2R, and BRS-3. Because AM-37 and ST-36 inhibit the ability of BA1 to increase cytosolic Ca2+ as well as increase EGFR and ERK tyrosine phosphorylation, they function as BB1R, BB2R, and BRS-3 antagonists. A particular advantage of AM-37 and ST-36 is that they will inhibit the growth of NSCLC cells if they have BB1R, BB2R, or BRS-3.

Author Contributions

TM and SM were responsible for the receptor binding studies. TM and NT were responsible for the cell culture and <span class="Chemical">calcium experiments. TM, PM, and IR-A were responsible for the transactivation and growth experiments. ML was responsible for the synthesis of the small molecules. TM and RJ were responsible for the writing of the manuscript.

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as potential conflicts of interest.